SPKM001, a next-generation, highly potent anti-SARS-COV2 human monoclonal antibody : announcement of Spiklmm and the Institut Pasteur

SpikImm, a Paris-Based biotechnology company and Institut Pasteur reports that SPKM001, their high affinity human monoclonal antibody, potently neutralizes the original SARS-CovV2 strain as well as its variants of concern, including the Alpha (formerly UK), Beta (South-African), Gamma (Brazilian), Delta and Delta Plus (Indian) variants. SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the SARS-CoV-2 Spike protein. SpikImm has recently signed an exclusive worldwide license agreement with the Institut Pasteur for the development of anti-SARS-CoV-2 (Covid-19) monoclonal antibodies (mAbs), including SPKM001

Find out more